LUOXIN PHARMACEUTICALS GROUP STOCK CO., LTD.

News Luoxin Pharmaceuticals Group Stock Co., Ltd.

Equities

002793

CNE1000026S7

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
4.74 ^CNY	-0.84%		+2.82%	-11.57%

04-26	Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-08	Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology	03-08	MT
Tranche Update on Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback Plan announced on February 2, 2024.	02-19	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback announced on February 2, 2024, has closed with 26,027,861 shares, representing 2.39% for CNY 99.99 million.	02-07	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	02-01	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. authorizes a Buyback Plan.	01-31	CI
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial	01-29	MT
Two Luoxin Pharma Drugs Selected in China’s National Drug Procurement Program	11-17	MT
Luoxin Health Technology Development Co., Ltd. announced that it has received CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.	11-16	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s LX-039 (Innovative Anti-Tumor Drug) Phase I Clinical Study Data Presented At ESMO 2023	23-10-23	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. agreed to acquire additional unknown stake in Luoxin Health Technology Development Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP) and Deyi Investment Management Co., Ltd. for CNY 1.	23-10-13	CI
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.	23-10-12	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Elects Li Meng as Non-Independent Directors	23-02-01	CI
Luoxin Pharmaceuticals' Injection Passes Regulatory Consistency Evaluation	23-01-11	MT
Luoxin Pharmaceuticals Gets Regulatory Nod for Anti-Baterial Infection Drug	22-12-28	MT
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Luoxin Pharmaceuticals Group Stock Co., Ltd.

Equities

002793

CNE1000026S7

Summary

Filters